research use only

Roflumilast PDE inhibitor

Name: Roflumilast
Brand: Selleck Chemicals
SKU: S2131
Availability: InStock
Rating: 5 (22 reviews)

Cat.No.S2131

Roflumilast is a selective inhibitor of PDE4 with IC50 of 0.2-4.3 nM in a cell-free assay.

Chemical Structure

Molecular Weight: 403.21

Jump to Mechanism of Action Cell Culture & Working Concentration Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.99%

99.99

Related Targets	P450 (e.g. CYP17) Dehydrogenase phosphatase PPAR HSP Vitamin Transferase Carbohydrate Metabolism Mitochondrial Metabolism Casein Kinase Serine/threonin kinase Lipoxygenase Phospholipase (e.g. PLA) Retinoid Receptor DPP ACE Peroxidases Amino Acids and Derivatives Fatty Acid Synthase FXR HMG-CoA Reductase Carbonic Anhydrase Lipase Decarboxylase DHFR IDO/TDO Hydroxylase PCSK9 OXPHOS ROR
Related Products	Rolipram IBMX (3-Isobutyl-1-methylxanthine) Icariin Mardepodect (PF-2545920) Cilomilast Deltarasin PF-8380 Enpp-1-IN-1 Ibudilast GSK256066 Ziritaxestat (GLPG1690) TAK-063 Doxofylline Diosgenin BRL-50481 S-(+)-Rolipram Mirodenafil Zatolmilast (BPN14770) OPB-171775 Olprinone Hydrochloride Linderane BI-409306 Mirodenafil Dihydrochloride Cilostamide Olprinone 3-Methylxanthine BW-A78U Mardepodect MBCQ Lodenafil

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Incubation Time	Activity Description
PBMC	Function assay		Inhibition of TNFalpha production in LPS-stimulated human PBMC preincubated before LPS challenge measured after 4 hrs by enzyme immunoassay, IC50=2e-05 μM
sf21 cells	Function assay		Inhibition of human full length PDE4A4 expressed in baculovirus infected sf21 cells, IC50=0.35 nM
HEK293 cells	Function assay	15 min	Inhibition of PDE4 expressed in HEK293 cells coexpressing cyclic nucleotide gated ion channel mutant assessed as inhibition of NECA-induced cAMP production treated 15 mins before NECA challenge measured after 45 mins by FLIPR assay
Click to View More Cell Line Experimental Data

Chemical Information, Storage & Stability

Molecular Weight	403.21	Formula	C₁₇H₁₄Cl₂F₂N₂O₃	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	162401-32-3	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	APTA 2217, B9302-107, BY 217, BYK 20869			Smiles	C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F

Solubility

In vitro
Batch:

DMSO : 81 mg/mL (200.88 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 15 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	30%PEG400 1 0.5%Tween80 2 5%propylene glycol Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	30.000mg/ml (74.40mM)	Taking the 1 mL working solution as an example, add 300 μL of 100 mg/ml clarified PEG400 stock solution to 5 μL of Tween80, mix evenly to clarify it; add 50 μL Propylene glycol to the above system, mix evenly to clarify it; then continue to add 645 μL ddH2O to adjust the volume. to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	PDE4B2 ^[1] (Cell-free assay) 0.2 nM PDE4A1 ^[1] (Cell-free assay) 0.7 nM PDE4B1 ^[1] (Cell-free assay) 0.7 nM PDE4A4 ^[1] (Cell-free assay) 0.9 nM PDE4C1 ^[1] (Cell-free assay) 3 nM PDE4C2 ^[1] (Cell-free assay) 4.3 nM
In vitro	Roflumilast displays anti-inflammatory and immunomodulatory in vitro. This compound inhibits LTB4 synthesis in human neutrophil with IC50 of 2 nM. It inhibits fMLP-stimulated ROS formation as luminol-enhanced CL in human neutrophils or eosinophils with IC35 of 4 nM, and 7 nM, repectively. The chemical inhibits LPS-stimulated TNF-α synthesis in monocytes with IC40 of 21 nM. It inhibits TNF-α synthesis in monocyte-derived dendritic cells with IC20 of 5 nM. This compound inhibits anti-CD3 and anti-CD28 antibody-stimulated proliferation of CD4+ T cells with IC30 of 7 nM. It inhibits anti-CD3 and anti-CD28 antibody-stimulated synthesis of IL-2, IL-4, IL-5, and IFN-v in CD4+ T cells with IC20 of 1 nM, IC30 of 7 nM, IC25 of 13 nM, and IC35 of 8 nM, respectively. ^[2]
In vivo	Roflumilast is activity against pulmonary inflammatory response related to COPD in animal model. This compound (5 mg/kg/day) induces reduction of neutrophils, macrophages, DC, B-cells, CD4⁺ T cells, CD8⁺ T cells in the lung of mice exposed to tobacco smoke for 7 month by 78%, 82%, 48%, 100%, 98%, and 88%, respectively. ^[3] It is an efficient inhibitor of lung fibrotic remodeling. This chemical dose-dependently diminishes total lung hydroxyproline after bleomycin, attaining about 47% inhibition at 5 mg/kg/day, paralleled by a reduction in lung αI(I) collagen transcripts and fibrotic lesions. It reduces oxidative stress in vivo. This compound (5 mg/kg/day) moderately reduces an increase in BAL fluid lipid hydroperoxides measured at day 14 after intratracheal bleomycin administration in mice. ^[4]
References	[1] https://pubmed.ncbi.nlm.nih.gov/20381629/ [2] https://pubmed.ncbi.nlm.nih.gov/11259554/ [3] https://pubmed.ncbi.nlm.nih.gov/18755021/ [4] https://pubmed.ncbi.nlm.nih.gov/19154443/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05684744	Completed	Psoriasis	Cairo University	January 9 2023	Phase 2\|Phase 3
NCT04655313	Completed	Psoriasis\|Plaque Psoriasis	Arcutis Biotherapeutics Inc.	November 30 2020	Phase 2
NCT04279119	Completed	Plaque Psoriasis	Arcutis Biotherapeutics Inc.	March 10 2020	Phase 1
NCT04156191	Completed	Atopic Dermatitis (Eczema)	Arcutis Biotherapeutics Inc.	December 23 2019	Phase 1
NCT03762330	Unknown status	Chronic Obstructive Pulmonary Disease	Fundacio d''Investigacio en Atencio Primaria Jordi Gol i Gurina\|Institut Catala de Salut	January 19 2019	Not Applicable

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Could you tell me which diluent you advise to use with it for in vivo applications in mice?

Answer:
For s2131, its in vivo formulation is 30% PEG400+0.5% Tween80+5% Propylene glycol up to 30mg/mL.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):